Early genetic diagnosis of inherited bone marrow failure syndromes facilitates timely transplant and lifelong surveillanceGenetic Factors May Influence Diagnosis of Bone Marrow Failure

Inherited bone marrow failure syndromes (IBMFS) comprise a heterogeneous group of rare genetic disorders defined by intrinsic defects of hematopoietic stem cells, resulting in chronic cytopenias, congenital anomalies, and a markedly increased risk of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and solid malignancies. Despite their clinical significance, IBMFS remain substantially underdiagnosed due to phenotypic heterogeneity, incomplete penetrance, and overlap with acquired marrow failure. This narrative review synthesizes current evidence on the pathogenesis, clinical manifestations, differential diagnosis, clonal evolution, and syndrome-specific management of major IBMFS in pediatric patients, with emphasis on recently published data and areas of active clinical controversy. Advances in next-generation sequencing (NGS) have expanded the recognized spectrum of IBMFS and demonstrated that germline predisposition underlies a significant proportion of cases initially classified as acquired marrow failure. Germline defects affecting DNA repair (Fanconi anemia, now comprising 23 complementation groups including the recently described FANCX), telomere maintenance (dyskeratosis congenita and telomere biology disorders), and ribosome biogenesis (Diamond–Blackfan anemia, Shwachman–Diamond syndrome) converge on shared pathogenetic mechanisms of hematopoietic stem cell exhaustion and clonal selection. GATA2 deficiency represents a transcription factor disorder with distinctive immunological and malignant features and is mechanistically related to SAMD9/SAMD9L-associated disorders through shared chromosome 7 instability. Congenital amegakaryocytic thrombocytopenia and severe congenital neutropenia represent additional single-lineage IBMFS that are frequently overlooked but carry their own malignant potential. Clonal evolution in IBMFS is biologically distinct from age-related clonal hematopoiesis and requires syndrome-specific surveillance and risk stratification. Hematopoietic stem cell transplantation (HSCT) remains the only curative option for hematologic disease but requires individualized conditioning and timing. Early recognition of IBMFS through systematic integration of clinical red flags and genetic diagnostics helps prevent diagnostic delays, guide appropriate management, inform timing of HSCT, and support lifelong multidisciplinary surveillance.